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ABSTRACT 
A microfluidic approach is developed to automate and simplify multiplexed metabolite assays. Solid matrix as-
sisted laser desorption ionization mass spectrometry (SMALDI-MS) on nanoporous thin films is suitable for ana-
lyzing small molecules, particularly metabolites, with a simple spot test. We present a system for blood sample 
preparation for metabolite analysis using centrifugal fluidics, coupled with derivatization and SMALDI-MS. This 
centrifugal microfluidic device enables semi-automated on-chip cleanup of blood samples, delivering a clean ma-
trix for MS detection. A derivatization reagent is applied in our work to label the target molecules with fluorous 
affinity tags, so that higher S/N is observed by SMALDI-MS. 
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INTRODUCTION 
In the analysis of the human metabolome, microfluidics and related technologies can be introduced to 
automate and miniaturize assays. The biological sample matrix is extremely complex, making extraction and 
purification of relatively hydrophilic, ionic, small target molecules extremely challenging for analysis [1], in a 
background of salt and proteins. We previously reported a polyester-toner centrifugal microchip to prepare small 
volumes of human serum samples for metabolites analysis by solid matrix laser desorption/ionization mass 
spectrometry (SMALDI-MS) [2]. That work involved off-chip mixing steps and serum preparation; here we 
present a semi-automated multichannel centrifugal microfluidic device for multi-step preparation of whole blood 
samples. The devices are assembled by laser cutting poly(methylmethacrylate) (PMMA) and pressure sensitive 
adhesive (PSA) to avoid wet chemical bonding procedures [3]. To facilitate liquid control and precise metering, 
dissolvable film(DF) based centrifugal-pneumatic valves [4,5] were introduced to automate on-chip decanting. 
The fluidic device removes proteins and lipids from blood, so that metabolites can be detected by directly spot test 
of SMALDI-MS in a clean matrix with high response and stable intensity. The SMALDI surface provides a 
necessary desalting step required for MS, eliminating the need for chromatographic preparation.  To validate the 
on-chip cleanup efficiency and broad target molecule coverage, the metabolites are detected in native form by 
SMALDI-MS and also by SMALDI-MS after derivatization. Derivatizing low mass analytes by using fluorous 
affinity tag shifts them to a higher mass, resulting in better S/N. Given the fluorous coating on the SMALDI 
surface, the fluorous tags also provide removal of salts by simple washing steps. The system reported here allows 





Figure 1:  3D view (A) and design for each unit (B) of centrifugal disc for blood sample preparation. 
The 15 cm diameter centrifugal microfluidic device consists of four layers of 1.5 mm-thick PMMA (Acrylite 
FF, Johnston plastics) and four layers of 127 μm-thick PSA. Features are cut by CO2 laser ablation 
(Epilog Zing Laser Series)  and aligned layers are laminated (Cheminstruments HL-100 rolling laminator) with 
100 psi. PSA layers serve as bonding layers between PMMA layers. The assembled disc is fixed on a centrifuge 
(Eppendorf 5415C centrifuge) by using an adaptor. Figure 1 represents the 3D view of the microfluidic design of 
one disc with three processing units for sample preparation.  
Blood was collected from a healthy female volunteer and loaded to plasma separation chamber (a). Then 50 
μL of separated plasma is metered by chamber (b) after on-chip blood cell separation in chamber (a). The metered 
plasma is diluted 3:1(v/v) with methanol in reservoir (c) for protein precipitation. C18 beads are preloaded in 
chamber (d) for lipid removal. Sample drying, re-dissolution and mixing with silica nanoparticles for further 
cleanup are performed in reservoir (e).  An oscillating spinning speed, below the DF valve burst frequency, mixes 
the suspensions to accelerate precipitation and adsorption on the nanoparticles. Then precipitates and 
nanoparticles are settled to the chamber bottom by a stable spinning speed.  The cleaned sample is pipetted out 
and spotted onto a SMALDI-chip for analysis, as our work flow in Figure 2 demonstrates. The SMALDI film 
which is a nanoporous silicon structure deposited by glancing angle in vacuum, is modified with a perfluoralkane 
monolayer [6].  
 
Figure 2: Work flow of on-chip sample preparation, followed by SMALDI-MS 
An 40 μL aliquot of the processed sample is vacuum dried and recovered by methanol for derivatization. The 
target molecules in the recovered supernatant were labeled with 3-(Perfluorohexyl)propan-1-ol in conc HCl, 
incubating 1 h at 65℃. Sample was then spotted on per-fluoroSiCl3 coated GLAD Si-films for SMALDI-MS.  
 
RESULTS AND DISCUSSION 
 
Figure 3: Blood sample on-chip preparation photo and corresponding mass spectrum with metabolite peaks. (taurine: 
124; aspartic acid: 132; glutamic acid: 146; uric acid: 167; citric acid: 191). 
After the on-chip processing, clear sample was obtained in the last chamber, shown in Figure 3 and the mass 
spectrum after cleanup shows tens of low mass metabolite peaks. We selected 6 analytes including amino acids 
and acids related to major diseases such as Parkinson's disease, stroke and cancer according to the Human 
Metabolome Database (HMDB), identified by their m/z values. 
 
Figure 4 :  Signal to noise ratio of different metabolites in serum samples prepared on-chip with different densities of C18 
beads (A) and silica nanoparticles (B). 
The signal to noise ratio (S/N) of the selected targets was employed to evaluate the sample preparation per-
formance with different suspension densities of C18 beads and silica particles. Figure 4A shows S/N from the 
sample preparation with 5% (m/v) C18 is larger than the sample prepared with lower C18 density, since the hy-
drophobic molecules in serum such as lipids are sufficiently removed. Figure 4B shows S/N of the sample pre-
pared with 0.05% (m/v) silica particles is higher than sample prepared with higher density of silica particles. Ac-
cording to previous study [7], this arises because silica nanoparticles can also adsorb some metabolites when 
protein is absent. In conclusion, densities of 5% (m/v) C18 and 0.05% (m/v) silica particles were selected to 
achieve optimized sample cleanup efficiency.  
 
Figure 5: Calibration curves of aspartic acid after on-chip cleanup (A) and glutamic acid after on-chip cleanup and deri-
vatization (B). 
The quantification of analytes in blood sample prepared on-chip was carried out by the standard addition 
method. As shown in Figure 5, linear regression was observed before and after derivatization. For glutamic acid 
in blood, the ion count was 3300 before labeling. After derivatization, higher ion counts were achieved due to the 
raised mass of the target molecules and better response of standard addition was observed because of the 
enhanced retention on the per-fluoro coated GLAD films during rinsing. The concentration of aspartic acid found 
in blood was 33.4 μM, with 85.8 μM for glutamic acid. These are very close to the concentration obtained for 
serum samples.  The results agree with NMR measurements, and the concentration range in human blood (Human 
Metabolome Database, HMDB, www.hmdb.ca).  Many reported studies for serum show higher concentration of 
aspartic acid than the database, because the concentration of aspartic acid in blood will increase with storage 
time[8]. Our result is more consistent with the database (HMDB: 20 ± 5 μM) because of the efficient automatic 
on-chip preparation of fresh blood. In addition, results from derivatization prove that the on-chip processed 
sample is clean enough for further metabolite labeling and improved detection.  
 
CONCLUSION 
The centrifugal fluid device works effectively for sample cleanup, allowing metabolite quantification from 
human whole blood.  The device, when coupled with the nanoporous GLAD thin films and per-fluoro labeling, 
provides sensitive, quantitative analysis. The method is competitive with chromatographic techniques, and is well 
suited to batch, clinical analysis of samples. 
 
ACKNOWLEDGEMENTS 
We thank the Natural Science and Engineering Research Council of Canada, and the Faculty of Science, 
University of Alberta for funding.  We thank G Lambkin of the Bioservices facility and the Mass Spectrometry 
Centre, University of Alberta for assistance and facilities. 
 
REFERENCES 
[1] Guo, K.; Li, L. Analytical chemistry, 2010, 8789-8793. 
[2] Zhao, Y.; Zhou, Y.; Harrison, D.J. Proceedings: Micro-TAS 2016, Dublin, Ireland, 2016, 701-702. 
[3] Hong, T. F.; Ju, W. J.; Wu, M. C.; et al. Microfluid and Nanofluid, 2010, 9, 1125-1133. 
[4] Smith, S.; Mager, D.; Perebikovsky, A.; et al. Micro machines, 2016, 7, 22.  
[5] Mishra, R.; Zapatero-Rodríguez, J.; Sharma, S.; et al. Sensors and Actuators B: Chemical, 2018, 668-675. 
[6] Zhou, Y.; Peng, C.; Harris, K. D.; et al. Analytical chemistry, 2017, 89(6), 3362-3369.  
[7] Zhang, B.; Xie, M.; Bruschweiler-Li, L.; et al. Analytical chemistry, 2015, 87(14), 7211-7217. 
[8] Demidov, V. V.; Potaman, V. N.; Frank-Kamenetskil, M. D.; et al. Biochemical pharmacology,   
     1994, 48(6),1310-1313. 
 
CONTACT 
* D. J. Harrison; phone: +1-780-492-2790; jed.harrison@ualberta.ca 
 
 
 
 
 
